Clinically supported, next-generation sequencing

For patients impacted by urologic malignancies, including renal, bladder, and prostate cancer, identifying whether their illness is genetic in origin is key to defining and classifying the tumor subtype. Because certain genetic variants have diagnostic, prognostic, and therapeutic associations, understanding the cancer’s genetic traits can help physicians better care for and direct treatment choices. Additionally, identifying pathogenic variants can support familial screening and genetic counseling for a variety of hereditary cancer syndromes.

Mayo Clinic Laboratories’ focused MayoComplete next-generation sequencing urology panels were carefully curated by a collaborative team of clinical experts, geneticists, and genetic counselors to include only clinically relevant genes. Focused, actionable, and cost-effective, our MayoComplete panels provide individualized insights that clarify the disease process and set patients on the right treatment path.

Learn more about our full suite of MayoComplete next-generation sequencing panels for hematologic and oncologic conditions.

MCKCP | MayoComplete Kidney Cancer Panel, Next-Generation Sequencing, Tumor

• Provides diagnostic, prognostic, and therapeutic insights based on assessment of 30 genes.

MCBPP | MayoComplete Bladder and Prostate Cancer Panel, Next-Generation Sequencing, Tumor

• Provides diagnostic, prognostic, and therapeutic insights based on assessment of 39 genes.

MCFRC | MayoComplete Renal Cell Carcinoma with Fibromyomatous Stroma Panel, Next-Generation Sequencing, Tumor

• Provides diagnostic insights based on assessment of four genes.

SDHMP | SDH Genes Mutation Analysis, Next-Generation Sequencing, Tumor

TFH | FH Mutation Analysis, Tumor